Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMBRANDT: Ezetimibe/Rosuvastatin vs Rosuvastatin in Diabetic Dyslipidemia with Hypertriglyceridemia
KCT0004577Phase 4Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM), dyslipidemia and hypertriglyceridemia comparing Ezetimibe/Rosuvastatin 10/5 mg composite pack with Rosuvastatin 10 mg (2 arms). Started Jul 2020; status: completed.
02
Drugs
ezetimiberosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on KCT0004577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004577.